Karyopharm Therapeutics (KPTI) reported $146M in revenue for fiscal 2025, +0.6% year on year. That ranks #2802 by revenue among 2853 SEC filers and #312 in Healthcare. It posted a net loss of −$196M for the same year. Revenue has grown 114.2% a year on average since 2016 ($154,000 then). The fiscal 2025 balance sheet shows $108M in total assets, $60.5M in cash and $169M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $146M | +0.6% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$90.7M | +$28.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$196M | −$120M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$75.4M | +$52.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $0 | −100.0% | FY20252025-12-31 |
| Total assetsAssets | $108M | −34.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$293M | −$107M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $60.5M | −3.1% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $169M | — | FY20212021-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $35.1M | −$22.4M | Open → |
| Q2 20262026-06-30 | $33.4M | −$67.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Karyopharm Therapeutics Inc.
- Ticker
- KPTI
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001503802
Filings
- 10-QAug 13, 2026Open filing →
- 10-QMay 14, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Elite PharmaceuticalsELTP | $149M | $44.9M |
| GrailGRAL | $147M | −$408M |
| Cronos GroupCRON | $147M | −$2.9M |
| Karyopharm TherapeuticsKPTI | $146M | −$196M |
| Infusystem HoldingsINFU | $143M | $6.6M |
| Beam TherapeuticsBEAM | $140M | −$80.0M |
| NRC HealthNRC | $137M | $11.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Karyopharm Therapeutics — Key figures |url=https://companiesranked.com/en/company/karyopharm-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Karyopharm Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/karyopharm-therapeuticsBibTeX
@misc{companiesranked-en-company-karyopharm-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{Karyopharm Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/karyopharm-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-049397 · February 13, 2026
{{cite web |title=Karyopharm Therapeutics — Key figures — 10-K (0001193125-26-049397) |url=https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/kpti-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.